Quarterly report pursuant to Section 13 or 15(d)

Agreements Related to Acquired Intellectual Property Rights (Details Narrative)

v3.19.2
Agreements Related to Acquired Intellectual Property Rights (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
May 12, 2018
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Research and development expense   $ 1,405,060 $ 1,148,811 $ 2,856,010 $ 1,712,029  
Lucid Diagnostics Inc [Member]            
Shares of common stock percentage   81.875%   81.875%   81.875%
CWRU License Agreement [Member] | Research and Development Expense [Member]            
Reimbursement of patent fees   $ 47,186 $ 78,148  
CWRU License Agreement [Member] | Lucid Diagnostics Inc [Member]            
Accrued license fee $ 273,000          
License fee as an initial requirement 50,000          
Payment of intellectual property $ 50,000          
Description of intellectual property payment Quarterly payments of $50,000 until such fee is paid-in-full, provided, however, the commencement of such quarterly payments is subject to Lucid Diagnostics Inc. consummation of a bona fide financing with an unrelated third-party in excess of $500,000.          
Description of equity interest percentage The right, in its sole discretion, to require the Company to transfer to CWRU a percentage, varying up to 100%, of the shares of common stock of Lucid Diagnostics Inc.          
Shares of common stock percentage 100.00%          
Research and development expense $ 75,000          
Tufts Patent License Agreement [Member]            
Reimbursement of patent fees   $ 29,390 $ 25,876 $ 33,258 $ 61,713